AkandaSTU:Y232 21 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates STU:Y232 with a GF Score™ of 21/100. The stock has 9 warning signs investors should review. Among 923 Drug Manufacturers companies, Akanda ranks better than 98.05% on this metric.
The historical rank and industry rank for Akanda's Days Payable or its related term are showing as below:
STU:Y232'
s Days Payable Range Over the Past 10 Years
Min: 1119.33 Med: 3220.1 Max: 6577.5
Current: 2773.21
During the past 7 years, Akanda's highest Days Payable was 6577.50. The lowest was 1119.33. And the median was 3220.10.
STU:Y232's Days Payable is ranked better than 98.05% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs STU:Y232: 2773.21
Akanda's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Akanda Days Payable Related Terms
Akanda Days Payable Historical Data
* Premium members only.
The historical data trend for Akanda's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:Y232 vs BFRI, BIOE, CABR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akanda's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akanda Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akanda's Days Payable distribution charts can be found below:
* The bar in red indicates where Akanda's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Akanda's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akanda (STU:Y232) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Akanda and its competitors. Over the past decade, Akanda's Days Payable has ranged from 1,119.33 to 6,577.50. According to the industry distribution chart, Akanda ranks #18 out of 923 companies in the Drug Manufacturers industry, placing it in the top 2%.
Is Akanda's Days Payable too high?
Akanda's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 1,119.33 to a high of 6,577.50. Based on the distribution chart, Akanda ranks #18 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Akanda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Akanda's Days Payable compare to BFRI and BIOE?
According to the Drug Manufacturers industry distribution chart, Akanda ranks #18 out of 923 companies for Days Payable. This places Akanda in the top 2% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. Historically, Akanda's own Days Payable has ranged from 1,119.33 to 6,577.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Akanda and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akanda's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akanda stock overvalued right now?
Akanda (STU:Y232) has a current Days Payable of 0.00. The current Days Payable is 0.00. Akanda's overall GF Score™ is 21/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Akanda (STU:Y232), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company is a medical cannabis & hemp and wellness platform company seeking to help people lives through improved access to high-quality and affordable products. The Company is also in the business of leasing fiber optic networks and telecommunication towers, through its subsidiary. The company has four reportable segments: Infrastructure, Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Infrastructure segment, which relates to the leasing and/or rental of fiber optic networks and telecommunication towers at First Towers in Mexico.
21GF Score
Get the complete analysis for STU:Y232
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:Y232 has been successfully added to your 
